111. Highlights from the SPD! - Ritlecitinib in adolescents with alopecia areata - UBA1 Variants Associated With VEXAS Syndrome - Role of Soluble IL-2 Receptor in Health & Disease - Botox for HA

Highlights from the SPD! Ritlecitinib in adolescents with alopecia areata [article]UBA1 Variants Associated With VEXAS Syndrome [article]Role of Soluble IL-2 Receptor in Health & Disease [article]Botox Type B for Hidradenitis Suppurativa [article] Check out our video content on VuMedi!: https://www.vumedi.com/channel/dermasphere/Luke's PDPC course and the Intermountain Derm Society meeting: ⁠⁠⁠https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE⁠⁠The University of Utah's Dermatology ECHO: ⁠⁠https://physicians.utah.edu/echo/dermatology-primarycare⁠⁠Connect with us!- Web: ⁠https://dermaspherepodcast.com/⁠- Twitter: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: https://www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle’s other podcast, SkinCast! ⁠https://healthcare.utah.edu/dermatology/skincast/⁠Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com⁠(a social platform for doctors to share knowledge)- ⁠https://www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!)